SU11248 (Sunitinib) Sensitizes Pancreatic Cancer to the Cytotoxic Effects of Ionizing Radiation

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 3, 2008, Pages 873-879

  Cuneo, Kyle C ^a   Geng, Ling ^b   Fu, Allie ^b   Orton, Darren ^a   Hallahan, Dennis E ^b,c,d   Chakravarthy, Anuradha Bapsi ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Pancreatic cancer; PDGFR; Radiosensitizer; SU11248; Sunitinib; VEGFR

Indexed keywords

CYTOTOXICITY; IONIZING RADIATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

PANCREATIC ADENOCARCINOMA CELLS; PANCREATIC CANCER; TUMOR GROWTH;

TUMORS;

BROXURIDINE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INDOLES; PANCREATIC NEOPLASMS; PYRROLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 44349119079     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.062     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 363 (2004) 1049-1057
3. Kalser M.H., and Ellenberg S.S. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
4. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase II trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (1999) 776-782 discussion 782-784
5. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 305 (2004) 1200-1210
6. Koshy M.C., Landry J.C., Cavanaugh S.X., et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 61 (2005) 955-966
7. Crane C.H., Ben-Josef E., and Small Jr. W. Chemotherapy for pancreatic cancer. (letter). N Engl J Med 350 (2004) 2713-2715
8. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high does (6000 rads) radiation alone, moderate dose radiation (400 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48 (1981) 1705-1710
9. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3606
10. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
11. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
12. Abrams T.J., Marray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2 (2003) 1011-1021
13. Mendel D.B., Laird A.S., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
14. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 1 (2006) 16-24
15. Demetri G., van Oosterom A., Garrett C., et al. Improved survival and sustained clinical benefit with SU11248 (SU) in patients with GIST after failure of imatinib mesylate (IM) therapy in a phase II trial. Gastrointestinal Cancers Symposium (2006) abstract no. 8
16. Casali P.G., Garret C.R., Blackstein M.E., et al. Updated results form a phase II trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol (Meeting Abstracts) 24 Suppl (2006) 9513
17. Cabebe E., and Wakelee H. Sunitinib: A newly approved small-molecule inhibitor of angiogenesis. Drugs Today 42 (2006) 387-398
18. Bardeesy N., and DePinho R.A. Pancreatic cancer biology and genetics. Nat Rev Cancer 2 (2002) 897-909
19. Xiong H.Q. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmocol 54 (2004) S69-S77
20. Saad E.D., and Hoff P.M. Molecular-targeted agents in pancreatic cancer. Cancer Control 11 (2004) 32-38
21. Fujioka S., Sclabas G.M., Schmidt C., et al. Function of nuclear factor kappB in pancreatic cancer metastasis. Clin Cancer Res 9 (2003) 346-354
22. McKenna W.G., Muschel R.J., Gupta A.K., et al. The RAD signal transduction pathway and its role in radiation sensitivity. Oncogene 22 (2003) 5866-5875
23. Zahn M., and Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19 (2004) 915-923
24. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological action of the vascular endothelial growth factor family. Cardiovas Res 49 (2001) 568-581
25. Zaider M. Concepts for describing the interaction of two agents. Radiat Res 123 (1990) 257-262